P
Piera Capranzano
Researcher at University of Catania
Publications - 211
Citations - 5720
Piera Capranzano is an academic researcher from University of Catania. The author has contributed to research in topics: Percutaneous coronary intervention & Coronary artery disease. The author has an hindex of 38, co-authored 192 publications receiving 4990 citations. Previous affiliations of Piera Capranzano include University of Florida.
Papers
More filters
Journal ArticleDOI
Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry
Davide Capodanno,Tommaso Gori,Holger Nef,Azeem Latib,Julinda Mehilli,Maciej Lesiak,Giuseppe Caramanno,Christoph Naber,Carlo Di Mario,Antonio Colombo,Piera Capranzano,Jens Wiebe,Aleksander Araszkiewicz,Salvatore Geraci,Stelios Pyxaras,Alessio Mattesini,Toru Naganuma,Thomas Münzel,Corrado Tamburino +18 more
TL;DR: "Real-world" outcomes of BVS showed acceptable rates of TLF at six months, although the rates of early and midterm scaffold thrombosis, mostly clustered within 30 days, were not negligible.
Journal ArticleDOI
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study.
Dominick J. Angiolillo,Piera Capranzano,Shinya Goto,Mohammed Aslam,Bhaloo Desai,Ronald K. Charlton,Yoshie Suzuki,Lyndon C. Box,Steven B. Shoemaker,Martin M. Zenni,Luis A. Guzman,Theodore A. Bass +11 more
TL;DR: Adjunctive treatment with cilostazol in T2DM patients on standard dual antiplatelet therapy enhances inhibition of platelet P2Y(12) signalling.
Journal ArticleDOI
Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary Intervention With Stent Implantation: A Systematic Review and Bayesian Network Meta-Analysis of 31 Studies and 17,882 Patients.
Sergio Buccheri,Gabriele Franchina,Sara Romano,Sebastiano Puglisi,Giuseppe Venuti,Paolo D'Arrigo,Bruno Francaviglia,Matteo Scalia,Antonio Condorelli,Marco Barbanti,Piera Capranzano,Corrado Tamburino,Davide Capodanno +12 more
TL;DR: Compared with CA, the use of intravascular imaging techniques for PCI guidance reduces the risk of cardiovascular death and adverse events and the treatment effect of IVUS on all-cause death was neutralized in the analysis restricted to randomized clinical trials.
Journal ArticleDOI
Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease
Davide Capodanno,Aasita Patel,Kodlipet Dharmashankar,José Luis Ferreiro,Masafumi Ueno,Murali Kodali,Salvatore D. Tomasello,Piera Capranzano,Naveen Seecheran,Andrew Darlington,Antonio Tello-Montoliu,Bhaloo Desai,Theodore A. Bass,Dominick J. Angiolillo +13 more
TL;DR: Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB2 levels.
Journal ArticleDOI
Usefulness of SYNTAX score to select patients with left main coronary artery disease to be treated with coronary artery bypass graft
Davide Capodanno,Piera Capranzano,Maria Elena Di Salvo,Anna Caggegi,Davide Tomasello,Glauco Cincotta,Marco Miano,Martina Patanè,Claudia Tamburino,Salvatore Tolaro,Leonardo Patanè,Antonio M. Calafiore,Corrado Tamburino +12 more
TL;DR: A SYNTAX score threshold of 34 may usefully identify a cohort of patients with left main coronary artery disease who benefit most from surgical revascularization in terms of mortality.